The strongest weakness is that the proposed therapeutic window may be narrower than the Theorist assumes. TRPML1 is not merely a TFEB trigger; it is embedded in lysosomal pH, PI(3,5)P2, membrane potential, iron handling, and fusion machinery. If aged neurons already have poor lysosomal acidification, lipofuscin load, and impaired reformation capacity, extra TRPML1 opening could accelerate failure rather than restore flux. The core question is whether the intervention increases complete autophagic flux or just creates more stalled vesicles with transient TFEB readouts.
For the sequential-priming hypothesis, rapamycin is a confounded primer. It changes mTORC1 signalling, translation, immune state, and metabolism, any of which could dominate the observed benefit. If rapamycin appears synergistic with a TRPML1 agonist, that does not prove temporal TRPML1 windowing; it may simply reduce substrate load or inflammation. The necessary control is a non-mTOR autophagy primer, plus TRPML1 loss-of-function or MCOLN1 knockdown rescue. Without those controls, the model risks attributing general autophagy effects to TRPML1 timing.
For the PINK1/Parkin hypothesis, the direction of interaction is uncertain. PINK1/Parkin loss may make TRPML1 more necessary because lysosomal replenishment becomes limiting, or less useful because mitophagosomes cannot be properly labelled and delivered. Both outcomes are plausible. The hypothesis needs a matrix experiment across PINK1, PARK2, LRRK2-G2019S, and wild-type human iPSC neurons, with dose-response curves for low, pulsed, and sustained agonism. Aggregate clearance alone is insufficient; it can improve while neuronal survival worsens.
The main falsification criteria should be strict. A candidate TRPML1 regimen fails if it improves TFEB nuclear localization but decreases lysosomal Ca2+ reserve, increases galectin-3 puncta, releases cathepsins, worsens mitochondrial membrane potential, or increases inflammatory signalling in microglia. It also fails if benefit disappears after washout, because neurodegeneration therapy requires chronic tolerability. The field has many examples where boosting degradation pathways helps short-term proteostasis but harms long-lived neurons under chronic stress.